Eli Lilly signs $1.9B gene-editing deal with Ascidian Therapeutics

Corroborated by 3 sources from 3 publishers

globalhealth2d ago

TL;DR

Reports differ across sources; according to finance.yahoo.com, eli Lilly signed a collaboration and licensing agreement with Boston-based Ascidian Therapeutics on Wednesday to research and develop treatments for inherited kidney diseases, with Ascidian eligible to receive up to $1.9 billion under the deal.

Sources